Compare FT & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FT | CDXS |
|---|---|---|
| Founded | 1988 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Major Chemicals |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 178.7M | 154.4M |
| IPO Year | N/A | 2008 |
| Metric | FT | CDXS |
|---|---|---|
| Price | $7.42 | $1.08 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $6.14 |
| AVG Volume (30 Days) | 56.8K | ★ 843.0K |
| Earning Date | 01-01-0001 | 11-12-2026 |
| Dividend Yield | ★ 7.85% | N/A |
| EPS Growth | N/A | ★ 43.82 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $138,590,000.00 |
| Revenue This Year | N/A | $4.97 |
| Revenue Next Year | N/A | $18.69 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 32.30 |
| 52 Week Low | $6.95 | $0.96 |
| 52 Week High | $8.35 | $2.98 |
| Indicator | FT | CDXS |
|---|---|---|
| Relative Strength Index (RSI) | 63.19 | 33.44 |
| Support Level | $6.95 | $0.96 |
| Resistance Level | $8.32 | $1.24 |
| Average True Range (ATR) | 0.09 | 0.09 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 94.12 | 12.50 |
Franklin Universal Trust is a closed-end management investment company focused on providing high current income while preserving capital. Its secondary objective is to achieve income growth through dividend increases and capital appreciation. The fund invests in two asset classes: high-yield bonds and utility stocks. It applies fundamental research to build a diversified high-yield bond portfolio and targets utility companies with attractive dividend yields and a history of increasing dividends.
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.